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The drug discovery process usually involves the discovery of a potent new chemical entity which has 
shown some activity on a target that is believed to be relevant in a certain type of disease. However, the 
structure and property of these putative drug molecules may have to be modified in order to ensure that 
they are able to exert the desired in vivo pharmacological effect. The candidate molecules usually have to 
be absorbed from the gastrointestinal system and therefore they must show appropriate solubility and 
permeability to be able to reach the target enzyme in vivo with a sufficient free biophase concentration at 
the site of action. This means that the physicochemical properties and the protein and phospholipid binding 
has to be optimized in order to achieve the desired in vivo ADMET and DMPK profile. The ADME studies 
usually require animal experiments or the use of biological samples, for example tissues which is expensive 
and involves time-consuming procedures. New technologies and approaches can accelerate this process. 
HPLC methodology is well established and used throughout the drug discovery process for analytical 
measurements of a compound’s purity and concentration in various biological samples such as blood, 
plasma and tissues. During the HPLC separation process, the compounds distribute between the mobile 
and the stationary phases. As different compounds have a different interaction with the stationary phase 
that is modified by the mobile phase, they move at a different speed through the chromatographic system 
resulting in different retention times. As these retention times are characteristic of the compound and the 
HPLC system and can be related to a compound’s dynamic distribution coefficient, they can be used to 
describe the properties of the compounds. When biomimetic stationary phases are used during 
chromatography, such as albumin, glycoprotein, and phospholipids, the calibrated retention times can be 
converted to binding constants representing these body components. These data can then be used to 
estimate the compound’s in vivo distribution behavior.  
In view of the important roles of HPLC methodology, ADMET & DMPK devoted a special issue to cover 
chromatographic technique in early drug discovery. Contributions were invited and received from several 
researchers who are well respected in this field to enlighten the readers of the more recent developments 
and applications in chromatography and in separation science as applied in support of drug discovery. This 
is presented as both original scientific papers describing the original contributions or review articles. 
The application of chromatography to predict skin penetration of compounds by Marti Rosés and his 
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team at University of Barcelona, Spain is described [1]. The application of pressure assisted Microemulsion 
Electro-kinetic Chromatography for lipophilicity determination has also been described by the same 
research group in a second contribution [2]. 
Automated measurements using biomimetic chromatography in support of drug discovery programme 
research at GSK are reviewed by Shenaz Bunally and Rob Young [3]. Similar efforts in Pfizer has been 
reviewed by Gilles Goetz and Marina Shalajeva in their contributions including their recent application of 
supercritical chromatography to measure the embedded polar surface area (EPSA) of molecules that could 
be related to their permeability [4].  
Klara Valko and co-workers from Genervon Biopharmaceuticals LLC (California, USA) and Bicycle 
Therapeutics (Cambridge, United Kingdom) have investigated the application of biomimetic 
chromatography to estimate lipophilicity, protein and phospholipid binding of new modalities such as linear 
and cyclic peptides as potential therapeutics [5]. The in vivo distribution behavior, cellular accumulation 
and brain penetration have been estimated using biomimetic HPLC measurements for GM6, a linear 
peptide discovered by Genervon Biopharmaceuticals, that has shown therapeutic potential in vivo for 
Amyotrophic Lateral Sclerosis (ALS) [6]. 
Oleg Krokhine and his research group at the University of Manitoba, Canada have demonstrated the 
possibility to predict peptide interaction with Immobilized Artificial Membranes using over 30 thousand 
peptides from tryptic digest to estimate their phospholipid binding and have compared these interactions 
with traditional reversed-phase chromatography that is most widely used for lipophilicity measurements 
[7].  
Several papers belonging to the chromatography thematic issue will be published in the next issue of 
ADMET and DMPK including the papers of Ciesla et al. [8], Tsopelas et al. [9] and Caron et al. [10].  
Lukasz Ciesla and his colleagues at the University of Alabama, USA have presented a new and innovative 
application of the immobilized artificial membrane stationary phase to bind membrane receptors on the 
surface called cellular membrane affinity chromatography (CMAC) that can enable the “fishing out” of 
potent molecules from complex mixtures [8].  
Fotios Tsopelas, Chrysanthos Stergiopoulos and Anna Tsantili-Kakoulidou have presented a 
comprehensive review article on the application of Immobilized Artificial Membrane Chromatography 
(IAM) in support of the drug design and discovery process [9]. 
Giulia Caron and her colleagues at the University of Torino, Italy have presented a review article about 
the block relevance approach which they developed to identify structure-property correlations that 
significantly enhanced the design of molecules with the right ADMET and DMPK properties [10]. 
The guest editor would like to thank all the contributors for their tremendous efforts made in presenting 
their work so lucidly. It is hoped that readers will be pleased to read these contributions and find them 
useful in their search for new drugs that will help to cure diseases and improve the quality of life of 
humans. 
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